Molecular imaging of rheumatoid arthritis: emerging markers, tools, and techniques
© Put et al.; licensee BioMed Central Ltd. 2014
Received: 16 October 2013
Accepted: 8 April 2014
Published: 15 April 2014
Skip to main content
© Put et al.; licensee BioMed Central Ltd. 2014
Received: 16 October 2013
Accepted: 8 April 2014
Published: 15 April 2014
Early diagnosis and effective monitoring of rheumatoid arthritis (RA) are important for a positive outcome. Instant treatment often results in faster reduction of inflammation and, as a consequence, less structural damage. Anatomical imaging techniques have been in use for a long time, facilitating diagnosis and monitoring of RA. However, mere imaging of anatomical structures provides little information on the processes preceding changes in synovial tissue, cartilage, and bone. Molecular imaging might facilitate more effective diagnosis and monitoring in addition to providing new information on the disease pathogenesis. A limiting factor in the development of new molecular imaging techniques is the availability of suitable probes. Here, we review which cells and molecules can be targeted in the RA joint and discuss the advances that have been made in imaging of arthritis with a focus on such molecular targets as folate receptor, F4/80, macrophage mannose receptor, E-selectin, intercellular adhesion molecule-1, phosphatidylserine, and matrix metalloproteinases. In addition, we discuss a new tool that is being introduced in the field, namely the use of nanobodies as tracers. Finally, we describe additional molecules displaying specific features in joint inflammation and propose these as potential new molecular imaging targets, more specifically receptor activator of nuclear factor κB and its ligand, chemokine receptors, vascular cell adhesion molecule-1, αVβ3 integrin, P2X7 receptor, suppression of tumorigenicity 2, dendritic cell-specific transmembrane protein, and osteoclast-stimulatory transmembrane protein.
Anatomical imaging techniques have long been used to diagnose and monitor rheumatoid arthritis (RA). Over the past decade, these techniques have dramatically improved. For example, it is now possible to detect bone erosions within 6 to 8 weeks after arthritis onset. Nevertheless, pure anatomical imaging of even the earliest structural damage misses the preceding molecular, cellular, and physiological changes in the very early stages of RA pathogenesis. Molecular imaging, currently being developed in many domains of medical research and diagnostic practice, offers the possibility to visualize the early functional changes in RA . This non-invasive technique allows early diagnosis, disease monitoring, guidance of treatment strategy, and possibly prediction of the outcome following the selected treatment. For example, patients can be selected for receiving a certain drug on the basis of the presence of the corresponding drug target, as was suggested for treatment of refractory monoarthritis patients with TNF-α antagonists after imaging with 99mtechnetium (Tc)-infliximab . Some RA drugs are relatively expensive; hence, it is important to determine which patients may respond to a proposed therapy and which ones will not. Additionally, patients who are likely to develop a more severe disease can be identified and selected for more intensive treatment or more frequent monitoring. Molecular imaging of joint pathology both in human and in animal models of arthritis will improve our knowledge of the pathogenesis of the disease. In animals, imaging can be performed before and at different time points after the clinical onset of arthritis in the same animal with minimal perturbation of the experiment, and therefore more information can be obtained with fewer animals. Questions such as ‘which are the earliest processes taking place in the pathogenesis of arthritis?’ and ‘which cells are most important in the disease process at which stage?’ might become answered by live-animal imaging with specific probes. In addition, imaging of early-onset inflammation requires sensitive techniques characterized by limited background and non-specific signals.
Macrophages are central effectors of synovial inflammation in RA and their abundance and degree of activation are correlated with disease severity . Macrophages act through release of inflammatory factors, phagocytosis, and antigen presentation . In RA, precursors from the monocyte/macrophage lineage are attracted from the blood to the inflamed joint and fuse to become active multinucleated osteoclasts, causing bone destruction.
T cells represent approximately 40% of immune cells in the synovial infiltrate of RA joints and have been implicated in different steps of RA pathology; they promote development of an autoimmune response and production of autoantibodies. Another role of T cells is the production of cytokines and induction of cytokine production by other cells . B cells contribute to RA by the production of autoantibodies, antigen presentation, and T-cell activation . They are indispensable for the development of arthritis as evident from the observation that the depletion of B cells abrogates the development of collagen-induced arthritis (CIA), an animal model for RA , and by the effectiveness of the B cell-depleting antibody, rituximab, that binds the CD20 surface molecule on B cells and inhibits the disease .
Synovial fibroblasts contribute to RA pathology by releasing matrix-degrading enzymes, including matrix metalloproteinases (MMPs) and cathepsins, which cause cartilage destruction . Osteoblasts differentiate from mesenchymal stem cells and produce bone matrix. At their surface, these cells express receptor activator of nuclear factor-kappa-B ligand (RANKL), which is essential for osteoclast formation . Blood vessel formation is elevated in RA joints and is associated with increased numbers of endothelial progenitor cells. Endothelial cells express cell adhesion molecules that facilitate rolling, binding, and transendothelial migration of leukocytes .
Conventional radiography is readily available, inexpensive, and reproducible. It allows the visualization of anatomical changes in established RA, such as erosions, joint space narrowing, and juxta-articular bone loss . Ultrasonography (grey-scale imaging, power Doppler) has been in use for over 30 years. It can be routinely used in the clinic and was found to be more sensitive and accurate than clinical examination or conventional radiography . This technique provides information on bone degradation, synovitis, and inflammation of tendons and entheses. Since ultrasound cannot penetrate bone, osteitis cannot be detected . Practical impediments are the lack of standard protocols for evaluation of RA and, therefore, strict dependence on the physician’s skills. Hence, implementation studies in daily practice are still needed. When magnetic resonance imaging (MRI) was introduced, it soon became evident that this technique outperforms radiography in detecting early bone erosions [17, 18]. MRI images are two- and three-dimensional and have a higher contrast resolution, consequently soft tissues can be distinguished more efficiently. With MRI it is possible to detect synovial hyperplasia, bone changes, and cartilage degradation but also signs of RA in the pre-erosive phase . It has now become the gold-standard modality for imaging synovitis in patients with early arthritis. Interestingly, several publications report accurate prediction of radiographic damage by MRI assessment of erosions or inflammation [19, 20]. In a study of 42 patients with early RA, baseline MRI erosion scores could predict the development of erosions that became visible by radiography after 1 year. Absence of MRI-detectable erosions predicted the absence of erosions after this time period .
Structural imaging techniques, though very useful, fail to provide information on the underlying biochemical processes. Therefore, novel imaging modalities using molecular probes such as optical imaging (bioluminescence, fluorescence, and near-infrared, or NIR; 600 to 750 nm) or nuclear imaging (scintigraphy; positron emission tomography, or PET; and single-photon emission computed tomography, or SPECT) are currently being improved for arthritis imaging.
The term optical imaging encompasses techniques, such as bioluminescence and fluorescence, that use light as the primary imaging method. Bioluminescence enables visualization of biological processes in vivo. It is a powerful tool for preclinical imaging but less applicable in a clinical setting as it requires administration of foreign enzymes. Fluorescence imaging holds more promise for clinical applications, especially since the development of NIR probes that allow deeper penetration into tissues and less background interference. Nuclear imaging techniques, such as scintigraphy, PET, and SPECT, use markers that are labeled with radioisotopes. Radioactive tracers provide the advantage of deep tissue penetration and low background compared with optical imaging techniques. PET and SPECT produce three-dimensional images and are more sensitive than structural imaging. SPECT is less expensive than PET and uses radiotracers with a longer half-life but has a lower resolution. Additionally, linkage of SPECT tracers requires modifications that might interfere with binding of the marker to the target.
Use of molecular imaging methods might facilitate early diagnosis, disease monitoring, and guidance of treatment strategy, but studies unequivocally demonstrating their value in daily practice are needed. Molecular imaging could be very useful for the selection of patients in phase II clinical trials that evaluate new drugs in a small patient group. The imaging allows measurement of the expression of a given therapeutic target in each individual patient. The level of this expression may be used to select those patients who are most likely to respond to the new therapy. Such an analysis may limit the number of patients who are required in a phase II proof-of-concept trial and may improve the chances of success, but will depend on factors such as the inter-individual variability and the response stratification prediction of the imaging. Imaging is also a powerful tool for animal experimentation; it enables researchers to gather data over a period of time in the same animal. Since the 1990s, molecular imaging has been applied to study arthritis in preclinical imaging of experimental animal models and has evolved from the use of simpler methods, such as autoradiography and planar gamma camera imaging, to more advanced techniques, including fluorescence, PET, and SPECT imaging, that show higher sensitivity and provide more detailed information. The development of the necessary equipment allowing small animal imaging has led to important progress in the field. Fluorescence imaging has greatly advanced as a whole-animal imaging technique and this is due mostly to the development of NIR fluorophores. The background signal in lower wavelengths strongly decreases sensitivity of fluorescence imaging but is significantly less in the NIR range. Nuclear imaging has become more accessible for preclinical research as well; PET and SPECT scanners have been adapted for imaging of small animals.
Development of new molecular imaging probes for introduction into the clinic is challenging. The regulatory pathway for diagnostics shares features with that for new therapeutics, but the potential revenue from commercialization is lower.
Available imaging agents for rheumatoid or experimental arthritis
Glucose metabolism, inflammation
Clinical use for detection of inflammation and cancer
Alterations in bone metabolism, osteoblastic activity
Clinical use for bone scanning
Cell membrane synthesis, inflammation
Clinical use for detection of prostate cancer
Trial in 10 patients with inflammatory joint disease
Circulating blood plasma proteins and leukocytes, inflammation
Clinical use for detection of inflammation
99mTc-polyclonal human immunoglobulin G
Increase in vascular permeability, hyperemia, inflammation
Multiple trials in patients with rheumatic disorders
Influx of leukocytes into inflamed tissue
Clinical use for infectious and inflammatory disorders
Multiple trials in patients with RA
Leukocytes (binds to receptors on neutrophils and mononuclear phagocytes)
Trial with 10 patients with RA
Case study in 1 patient with RA, trial in 6 patients with RA
Trials in 7 patients with RA, 2 psoriatic arthritis patients, and 38 patients with RA
Trial in 4 patients with active RA
Multiple trials with patients with RA
Phase 3 study (NCT01590966)
Trials in 6 patients with RA and 20 patients with chronic inflammatory autoimmune disease
Specific molecular markers
Mononuclear phagocyte trafficking (binds CD14 and CD11b)
Trials for tumoral, inflammatory and infectious diseases
Preclinical, rabbit antigen-induced arthritis
Endothelium activation and macrophage recruitment (binds to somatostatin receptor)
Clinical use for detection of tumors
Trial in 14 patients with RA
Monocytes and macrophages (binds to peripheral benzodiazepine receptors)
Trials in 11 patients with RA, 6 patients with RA, and 29 patients with arthralgia
Activated vascular endothelium
Preclinical, rat adjuvant arthritis
99mTc-anti-E-selectin Fab/(Fab′)2 fragment
Activated vascular endothelium
Trial in 26 patients with RA
Activated vascular endothelium
Preclinical, CIA, and TNF-α-induced paw edema
Apoptosis (binds to phosphatidylserine)
Multiple trials in cancer patients
Preclinical, murine arthritis model
99mTc-folic acid (EC20)
Activated macrophages, folate receptor
Phase 2 study in patients with autoimmune disease (NCT00588393)
Activated macrophages, folate receptor
Mouse arthritis models
Activated macrophages, folate receptor
Preclinical, methylated bovine serum albumin-induced arthritis
64Cu-/18 F-galacto-arginine-glycine-aspartic acid
Activated macrophages, osteoclasts, endothelial cells
Clinical use, tumor angiogenesis
Preclinical, osteopetrosis, and osteoporosis mouse models
NIR-matrix metalloproteinase-specific probe
Sites of matrix degradation and inflammation
Preclinical, CIA, rat OA
99mTc-anti-macrophage mannose receptor
Subset of macrophages
Several biologicals approved for the treatment of RA have been radiolabeled and evaluated for imaging, and this provides a number of advantages. These drugs are already being developed commercially, and their safety has been assessed. Radiolabeled therapeutics might provide an earlier, more specific diagnosis and facilitate monitoring of treatment efficacy. Importantly, confirmation of the presence of the target in the patient before treatment initiation provides the possibility of personalized therapy, which can significantly reduce treatment costs. In this context, anti-CD3 [46–48], anti-CD4 [42–45], anti-CD20 [53, 54], and anti-TNF-α (infliximab [2, 50] and adalimumab [51, 52]) have been evaluated for imaging of RA, and most perform relatively well. An exception is IL-1 receptor antagonist (anakinra), which failed to show any specific localization in synovia of RA patients as compared with healthy synovia . As evident from clinical trials, uptake of radiolabeled monoclonal anti-CD3 antibodies (OKT-3), which target all T cells, was detectable in inflamed joints of patients with RA and levels correlated with inflammation scores from physical examination [46–48]. Anti-CD4 antibodies (MAX.16H5) target a more specific subset of T lymphocytes. These antibodies were also evaluated for visualization of inflammatory foci in patients with RA [42–45]. Early studies on the specificity of the antibody signal yielded conflicting results , but this specificity was later confirmed in a study using Fab fragments. A higher accumulation of anti-CD4 Fab′ fragments compared with control Fab′ fragments was clearly shown in adjuvant-induced arthritis . Rituximab, a chimeric monoclonal anti-CD20 antibody, is licensed for treatment of RA and has demonstrated good efficacy in a subset of patients . 99mTc-rituximab was shown to localize in inflamed joints of patients with RA [53, 54]. Here, an interesting intra-articular and inter-individual variability was exposed, providing an explanation for the failure of anti-CD20 therapy in certain patients . Finally, with respect to anti-TNF-α, imaging of patients with active RA by using 99mTc-anti-TNF-α showed a high correlation with inflammation detected by MRI and proved to be more sensitive than clinical examination . In addition, Conti and colleagues  reported that imaging with anti-TNF-α in patients with active arthritis just before treatment with infliximab could predict the efficacy of the anti-TNF-α therapy.
As evident from Table 1, these radiopharmaceuticals have been evaluated in trials dating back several years; for some of them, no real implementation in imaging has been reported in recent years. Further development of radiolabeled drugs for imaging purposes is subjected to important limitations: (a) the safety issues of murine and chimeric monoclonal antibodies; problems with immunogenicity are now being handled by humanization of the antibodies. (b) The safety profile of the pharmaceutical. Administration of anti-CD3 antibodies, for example, may cause serious adverse effects in some patients, such as the cytokine release syndrome. (c) The inefficacy of certain drugs in patients with RA. As mentioned, anti-CD4 antibody was demonstrated to have potential for location of inflammatory regions, but the lack of therapeutic results in RA has halted further development for imaging. (d) The high costs associated with development and production of these therapies.
In our opinion, radiolabeled anti-CD20 and anti-TNF-α antibodies show the most potential for clinical use. Their effectiveness as treatment for RA has been established, and the first results on identification of patients who will respond to therapy look promising. Further implementation studies demonstrating their value in selecting patients for specific therapies are needed. Currently, conflicting results are found in the literature - coming mostly from registries - about switching to another mode of action or to another TNF blocker in patients failing their first anti-TNF treatment [76, 77]. In the future, the use of radiolabeled antibodies in appropriate randomized studies could help to produce more solid data that might give guidance to clinicians.
Molecular imaging in animal models is necessary for the development of new tracers but can also be used as an additional objective parameter to assess arthritis in an experimental context, thereby providing detailed information on the disease process. Tracers have evolved to target molecules more specifically than 18 F-FDG or 99mTc-MDP, which visualize general processes (glucose metabolism and bone turnover), and we can see an evolution in the use of more sophisticated techniques for preclinical research. An example of the technical evolution can be seen in the development of tracers that target the folate receptor, a 38-kDa glycosyl-phosphatidylinositol-anchored protein that binds folic acid . The folate receptor is expressed at very low levels in most tissues in homeostatic conditions, except for the kidneys and placenta. Under these circumstances, folic acid is taken up by carriers . Expression of the folate receptor in pathogenic conditions seems to be restricted to several cancer cells and activated macrophages. Interestingly, high-level expression of this receptor was found in activated synovial macrophages from patients with RA , a feature that has been exploited in imaging. In 2002, Turk and colleagues  published a study in which the folate receptor was targeted in rats with adjuvant-induced arthritis by using 99mTc-labeled folic acid. Gamma scintigraphy was applied to produce images of the inflamed paws, and uptake could be detected in arthritic joints . However, the resolution of this technique is very low. Chen and colleagues  developed a fluorescence-labeled folate probe (NIR2-folate) that allowed improved resolution in two mouse models of arthritis and the possibility of detecting arthritis at an early time point. So far, however, fluorescent imaging is being hindered by limited tissue penetration and is not yet optimized for use in patients with RA. Recently, an improved PET tracer (18 F-polyethylene glycol-folate) targeting the folate receptor was shown to hold promise for imaging RA in patients, as it was successfully used in an antigen-induced arthritis model . A folate receptor-targeting agent, 99mTc-EC20 (FolateScan), has been produced and evaluated in the clinic for the assessment of inflammation in joints of patients with RA or other diseases [67, 80]. In a study including 40 RA patients with active and inactive disease, joint involvement was assessed by screening with FolateScan. The number of actively involved joints identified by FolateScan correlated with erythrocyte sedimentation rates and C-reactive protein levels. Larger numbers of actively involved joints were detected with FolateScan than were identified by clinical examination. It was concluded that imaging with FolateScan may be a more sensitive method than physical examination for assessing disease activity . Upregulation of the folate receptor in activated macrophages is also being exploited for targeting of folate-linked drugs to these macrophages in RA [81, 82]. Imaging with FolateScan might help to predict the success rate of this technique.
Vascular endothelium, activated in inflammatory processes, transiently expresses the surface glycoprotein E-selectin in response to cytokines such as IL-1β and TNF-α. Selectins facilitate tethering and rolling of leukocytes on endothelium. These mechanisms commence early in the pathogenesis of arthritis. Fluorescently labeled anti-E-selectin antibodies were successfully used for imaging in a mouse model for RA, enabling detection of subclinical manifestations, monitoring effects of therapy, and quantification of disease . In patients with RA, 99mTc-anti-E-selectin-Fab appeared to be suitable for scintigraphic imaging of synovitis and showed a higher specificity than 99mTc- hydroxymethylene diphosphonate bone imaging .
Intercellular adhesion molecule-1 (ICAM-1) is another potential target for imaging of arthritis as it was demonstrated to be expressed on synovial endothelial cells and mice deficient in ICAM-1 showed a reduction in arthritis incidence and severity . In CIA, antibodies targeting ICAM-1 were conjugated to gadolinium diethylenetriamine pentaacetic acid and were able to detect early inflammatory symptoms before the onset of the chronic destructive phase .
In arthritic joints, increased apoptotic cells are detected in the synovial membrane . These cells can be imaged by the use of radiolabeled annexin V that binds to phosphatidylserine, which is associated with the inner leaflet of the plasma membrane. It was found that 99mTc-annexin could visualize arthritic joints before the onset of bone destruction .
Inflammatory cytokines, such as IL-1β and TNF-α, stimulate the production of MMPs that degrade the extracellular matrix. Levels of MMPs increase in the serum and the synovial fluid of patients with RA. MMP-1, −2, −3, −9, and −13 appear to be most important in RA. Recently, Ryu and colleagues  demonstrated the use of an MMP-3-specific polymeric probe for visualization of arthritis by NIR fluorescence imaging. The probe was developed by the conjugation of a NIR dye, an MMP substrate peptide, and a quencher to chitosan nanoparticles. Imaging with this probe allowed early diagnosis of arthritis in mice with CIA. More specifically, at 2 weeks after immunization, before any signs of structural or anatomical changes, a signal from the MMP-3 probe could be detected .
Development of these molecular markers is still in its infancy; many have only recently been evaluated for imaging of arthritis in preclinical models. Some show potential for further development, such as MMP-specific probes, which are being commercialized and are entering research labs. Others are less promising for the future and this is due mostly to lower specificity. The targeted cell type might not be exclusively expressed in the inflamed joint or the probe might bind to irrelevant targets, resulting in non-specific signals and low target-to-background ratios.
Molecules in the following section were chosen for discussion because they have been shown, or suggested, to be involved in the pathogenesis of arthritis through functional preclinical studies and expression studies in animal models or patients.
RANKL is a type I-membrane protein of the TNF receptor superfamily, expressed on osteoblasts and T cells. RANKL knockout mice exhibit severe osteopetrosis because of a complete absence of osteoclasts. Furthermore, the importance of RANK-RANKL signaling for bone destruction in arthritis has been demonstrated in several studies [87, 88]. Inhibition of RANKL by denosumab, a human monoclonal antibody, has been effective for the treatment of RA-associated bone loss  and bone metastasis in cancer . The receptor for RANKL, RANK, can be detected on pre-osteoclasts in the blood as well as on mature osteoclasts . Importantly, RANK has already proven to be a potential marker for the detection of bone metastasis [92–94]. RANK and RANKL can thus be considered valuable molecular targets for the treatment of bone loss and have great value as markers for RA-associated bone pathology.
Chemokines and their receptors are involved in the recruitment of leukocytes to the site of inflammation; they are key molecules in the pathogenesis of RA and present possible targets for imaging. CCR1 and CCR5 are the ones most implicated in RA. CCR1 is abundantly expressed by macrophages in the inflamed synovium and peripheral blood monocytes of patients with RA, suggesting an important role in recruitment of leukocytes from the circulation. A trial involving 160 patients with RA showed evidence of a beneficial effect of treatment with the small-molecule CCR1 antagonist CCX354-C . CCR5 is highly expressed in the rheumatoid synovium, particularly by T helper (Th)1 lymphocytes . Antagonists of CCR5 have proven to be capable of inhibiting the development of collagen- and adjuvant-induced arthritis [97, 98].
VCAM-1 is thought to be responsible for recruitment and retention of leukocytes in the inflamed synovium. It is found on fibroblast-like synoviocytes in the synovial lining layer and is upregulated upon stimulation with various cytokines . As mentioned, nanobodies targeting VCAM-1 have proven their worth in imaging of atherosclerotic lesions. The expression of VCAM-1 in arthritis suggests that these nanobodies might also be useful in imaging of arthritic joints.
Integrins, a large family of heterodimeric transmembrane glycoproteins, mediate cell-cell and cell-matrix interactions. Their expression is upregulated in the pro-inflammatory environment of the rheumatoid synovium and leads to production of matrix-degrading enzymes and cytokines . Vitaxin, a humanized monoclonal antibody that blocks the interactions of αvβ3 with its ligands, was tested as treatment for RA in clinical trials . Mature and active osteoclasts express αvβ3; consequently, inhibition or deficiency of the β3 integrin was shown to cause impaired differentiation and function of osteoclasts . Imaging studies were performed with the tripeptide Arg-Gly-Asp (RGD), which binds with high affinity to αvβ3. PET imaging with 64Cu-labeled RGD allowed detection of changes in osteoclast numbers in mouse models for osteopetrosis or osteoporosis , suggesting that 64Cu-RGD may be suitable for imaging of osteoclast changes in RA.
Another cell surface molecule implicated in the pathogenesis of RA is the purinoreceptor P2X7, which was shown to be expressed by synoviocytes from RA joints. P2X7 is expressed by various cells, including osteoblasts and osteoclasts, and has been implicated in the formation of multinuclear cells. Triggering of this receptor results in enhanced IL-6 secretion and its absence was shown to result in a loss of ATP-dependent leukocyte function, including IL-1β production and L-selectin shedding . In animal models of arthritis, deficiency of the P2X7 receptor is associated with lower incidence and severity of arthritis .
Suppression of tumorigenicity 2 (ST2) is a member of the Toll-like/IL-1 receptor superfamily that participates in inflammatory processes, such as production of Th2 cytokines. The ST2/IL-33 pathway has been implicated in RA pathogenesis, and treatment of CIA with ST2-Fc fusion protein ameliorated the disease and downregulated production of IL-6, IL-12, and TNF-α .
Dendritic cell-specific transmembrane protein (DC-STAMP) and osteoclast-stimulatory transmembrane protein (OC-STAMP) are highly expressed by osteoclasts and essential for the fusion of macrophages to multinuclear cells and bone degradation . DC-STAMP was suggested to be a marker for circulating osteoclast precursors in inflammatory arthritis as it was found to be increased on peripheral blood mononuclear cells of patients with psoriatic arthritis . DC-STAMP and OC-STAMP could be valuable for therapy development and imaging of osteoclasts in arthritis.
High selectivity of molecular imaging probes is mandatory and represents the most important aspect to consider when developing new candidates for imaging. A second challenge to consider is resolution; theoretically, molecular imaging could also help in showing specific localizations of inflammation, distinguishing enthesitis from arthritis in spondyloarthritis versus RA, but this would require techniques with better resolution. To qualify the cost-effectiveness of a new marker, the molecular imaging method should have an impact on patient management. As stated above, molecular imaging methods might be of help in designing and evaluating proof-of-concept phase I and II trials assessing specific targets. The use of these tools, however, will become established only if they facilitate daily treatment practice in making an appropriate choice for the best treatment option or are able to guide the physician in tapering expensive treatment if a specific state of prolonged remission has been reached. Ultimately, as stated in a recent editorial by Smolen and Aletaha , better markers will be needed to make a transition toward real personalized medicine.
The field of molecular imaging has grown substantially in the past two decades; tools and techniques have evolved, and new molecular markers are being identified. Molecular imaging will be of help in a preclinical context by offering a reliable and subjective manner to assess the disease severity and by providing more detailed knowledge of the disease process. Some of the markers will enter the clinic to facilitate diagnosis, monitoring of disease progression, and determination of treatment strategy in a subset of patients. Finally, an important role for molecular imaging may be situated in the assessment of efficacy of new drugs and in the design and evaluation of clinical trials.
Dendritic cell-specific transmembrane protein
Intercellular adhesion molecule-1
Macrophage mannose receptor
Magnetic resonance imaging
Osteoclast-stimulatory transmembrane protein
Positron emission tomography
Receptor activator of nuclear factor-kappa-B
Receptor activator of nuclear factor-kappa-B ligand
Single-photon emission computed tomography
Suppression of tumorigenicity 2
Tumor necrosis factor-alpha
Vascular cell adhesion molecule-1.
We are grateful to Prof. Alfons Billiau for critical revision of the manuscript. Our work was supported by grants from the Regional Government of Flanders (GOA program), the Belgian Federal Government (Interuniversitary Attraction Poles program), and the Government Agency for Innovation by Science and Technology (IWT, Strategisch Basisch Onderzoek project coordinated by Patrick De Baetselier, Laboratory of Cellular and Molecular Immunology, VIB Laboratory of Myeloid Cell Immunology, Brussels, Belgium).
This article is published under license to BioMed Central Ltd. The licensee has exclusive rights to distribute this article, in any medium, for 6 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.